{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T05:33:14Z","timestamp":1794807194822,"version":"4.9.1"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background and Aims<\/jats:title>\n            <jats:p>Atezolizumab plus bevacizumab (AtezoBev) is the standard of care for first\u2010line treatment of unresectable HCC. No evidence exists as to its use in routine clinical practice in patients with impaired liver function.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Approach and Results<\/jats:title>\n            <jats:p>In 216 patients with HCC who were consecutively treated with AtezoBev across 11 tertiary centers, we retrospectively evaluated treatment\u2010related adverse events (trAEs) graded (G) according to Common Terminology Criteria for Adverse Events v5.0, including in the analysis all patients treated according to label (<jats:italic toggle=\"yes\">n<\/jats:italic> = 202, 94%). We also assessed overall survival (OS), progression\u2010free survival (PFS), overall response (ORR), and disease control rates (DCR) defined by Response Evaluation Criteria in Solid Tumors v1.1. Disease was mostly secondary to viral hepatitis, namely hepatitis C (<jats:italic toggle=\"yes\">n<\/jats:italic> = 72; 36%) and hepatitis B infection (<jats:italic toggle=\"yes\">n<\/jats:italic> = 35, 17%). Liver function was graded as Child\u2010Pugh (CP)\u2010A in 154 patients (76%) and CP\u2010B in 48 (24%). Any grade trAEs were reported by 143 patients (71%), of which 53 (26%) were G3 and 3 (2%) G4. Compared with CP\u2010A, patients with CP\u2010B showed comparable rates of trAEs. Presence and grade of varices at pretreatment esophagogastroduodenoscopy did not correlate with bleeding events. After a median follow\u2010up of 9.0 months (95% CI, 7.8\u201310.1), median OS was 14.9 months (95% CI, 13.6\u201316.3), whereas median PFS was 6.8 months (95% CI, 5.2\u20138.5). ORR and DCR were respectively 25% and 73%, with no difference across CP classes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study confirms reproducible safety and efficacy of AtezoBev in routine practice. Patients with CP\u2010B reported similar tolerability compared with CP\u2010A, warranting prospective evaluation of AtezoBev in this treatment\u2010deprived population.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.32468","type":"journal-article","created":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T11:40:18Z","timestamp":1647862818000},"page":"1000-1012","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":221,"title":["Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child\u2010Pugh A and B cirrhosis: A real\u2010world study"],"prefix":"10.1097","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9164-3671","authenticated-orcid":false,"given":"Antonio","family":"D\u2019Alessio","sequence":"first","affiliation":[{"name":"Department of Surgery & Cancer,Imperial College London,Hammersmith Hospital,London,UK"},{"name":"437807,Department of Biomedical Sciences,Humanitas University,Pieve Emanuele, Milan,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia Angela Maria","family":"Fulgenzi","sequence":"additional","affiliation":[{"name":"Department of Surgery & Cancer,Imperial College London,Hammersmith Hospital,London,UK"},{"name":"Division of Medical Oncology,Policlinico Universitario Campus Bio\u2010Medico,Rome,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoshi","family":"Nishida","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Kindai University Faculty of Medicine,Osaka,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1010-0975","authenticated-orcid":false,"given":"Martin","family":"Sch\u00f6nlein","sequence":"additional","affiliation":[{"name":"37734,Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology,University Medical Center Hamburg\u2010Eppendorf,Hamburg,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"von Felden","sequence":"additional","affiliation":[{"name":"37734,Department of Medicine,University Medical Center Hamburg\u2010Eppendorf,Hamburg,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kornelius","family":"Schulze","sequence":"additional","affiliation":[{"name":"37734,Department of Medicine,University Medical Center Hamburg\u2010Eppendorf,Hamburg,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Wege","sequence":"additional","affiliation":[{"name":"37734,Department of Medicine,University Medical Center Hamburg\u2010Eppendorf,Hamburg,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent E.","family":"Gaillard","sequence":"additional","affiliation":[{"name":"F. Hoffmann\u2010La Roche Ltd.,Basel,Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwaar","family":"Saeed","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology,Department of Medicine,Kansas University Cancer Center,Kansas City,Kansas,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Wietharn","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology,Department of Medicine,Kansas University Cancer Center,Kansas City,Kansas,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Hildebrand","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology,Department of Medicine,Kansas University Cancer Center,Kansas City,Kansas,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology,Department of Medicine,Tisch Cancer Institute,Mount Sinai Hospital,New York,New York,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celina","family":"Ang","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology,Department of Medicine,Tisch Cancer Institute,Mount Sinai Hospital,New York,New York,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas U.","family":"Marron","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology,Department of Medicine,Tisch Cancer Institute,Mount Sinai Hospital,New York,New York,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Weinmann","sequence":"additional","affiliation":[{"name":"University Medical Center Mainz,Mainz,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter R.","family":"Galle","sequence":"additional","affiliation":[{"name":"University Medical Center Mainz,Mainz,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8782-8729","authenticated-orcid":false,"given":"Dominik","family":"Bettinger","sequence":"additional","affiliation":[{"name":"Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases),Faculty of Medicine,Freiburg University Medical Center,University of Freiburg,Freiburg,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Bengsch","sequence":"additional","affiliation":[{"name":"Department of Medicine II (Gastroenterology, Hepatology, Endocrinology and Infectious Diseases),Faculty of Medicine,Freiburg University Medical Center,University of Freiburg,Freiburg,Germany"},{"name":"University of Freiburg,Signalling Research Centres BIOSS and CIBSS,Freiburg,Germany"},{"name":"German Cancer Consortium (DKTK), partner site,Freiburg,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Vogel","sequence":"additional","affiliation":[{"name":"Hannover Medical School,Hannover,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Balcar","sequence":"additional","affiliation":[{"name":"27271,Division of Gastroenterology & Hepatology,Department of Internal Medicine III,Medical University of Vienna,Vienna,Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4904-5133","authenticated-orcid":false,"given":"Bernhard","family":"Scheiner","sequence":"additional","affiliation":[{"name":"27271,Division of Gastroenterology & Hepatology,Department of Internal Medicine III,Medical University of Vienna,Vienna,Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei\u2010Chang","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Department of Medicine,Taipei Veterans General Hospital,Taipei,Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5241-5425","authenticated-orcid":false,"given":"Yi\u2010Hsiang","family":"Huang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology,Department of Medicine,Taipei Veterans General Hospital,Taipei,Taiwan"},{"name":"Institute of Clinical Medicine,School of Medicine,National Yang Ming Chiao Tung University,Taipei,Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suneetha","family":"Amara","sequence":"additional","affiliation":[{"name":"3627,Division of Hematology\/Oncology,East Carolina University,Greenville,North Carolina,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahvish","family":"Muzaffar","sequence":"additional","affiliation":[{"name":"3627,Division of Hematology\/Oncology,East Carolina University,Greenville,North Carolina,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Rafeh","family":"Naqash","sequence":"additional","affiliation":[{"name":"3627,Division of Hematology\/Oncology,East Carolina University,Greenville,North Carolina,USA"},{"name":"Medical Oncology\/TSET Phase 1 Program,Stephenson Cancer Center,University of Oklahoma,Norman,Oklahoma,USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Cammarota","sequence":"additional","affiliation":[{"name":"437807,Department of Biomedical Sciences,Humanitas University,Pieve Emanuele, Milan,Italy"},{"name":"Medical Oncology and Hematology Unit,Humanitas Cancer Center,IRCCS Humanitas Research Hospital,Rozzano,Milan,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Personeni","sequence":"additional","affiliation":[{"name":"437807,Department of Biomedical Sciences,Humanitas University,Pieve Emanuele, Milan,Italy"},{"name":"Medical Oncology and Hematology Unit,Humanitas Cancer Center,IRCCS Humanitas Research Hospital,Rozzano,Milan,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Pressiani","sequence":"additional","affiliation":[{"name":"Medical Oncology and Hematology Unit,Humanitas Cancer Center,IRCCS Humanitas Research Hospital,Rozzano,Milan,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohini","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Surgery & Cancer,Imperial College London,Hammersmith Hospital,London,UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7260-532X","authenticated-orcid":false,"given":"Matthias","family":"Pinter","sequence":"additional","affiliation":[{"name":"27271,Division of Gastroenterology & Hepatology,Department of Internal Medicine III,Medical University of Vienna,Vienna,Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Cortellini","sequence":"additional","affiliation":[{"name":"Department of Surgery & Cancer,Imperial College London,Hammersmith Hospital,London,UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Kudo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Kindai University Faculty of Medicine,Osaka,Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenza","family":"Rimassa","sequence":"additional","affiliation":[{"name":"437807,Department of Biomedical Sciences,Humanitas University,Pieve Emanuele, Milan,Italy"},{"name":"Medical Oncology and Hematology Unit,Humanitas Cancer Center,IRCCS Humanitas Research Hospital,Rozzano,Milan,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Pinato","sequence":"additional","affiliation":[{"name":"Department of Surgery & Cancer,Imperial College London,Hammersmith Hospital,London,UK"},{"name":"Division of Oncology,Department of Translational Medicine,University of Piemonte Orientale,Novara,Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"issue":"1","key":"hep32468-bib-0001-20250824","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"hep32468-bib-0003-20250824","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"hep32468-bib-0004-20250824","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia\u2010Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double\u2010blind, placebo\u2010controlled trial","volume":"10","year":"2009","journal-title":"Lancet Oncol"},{"issue":"10126","key":"hep32468-bib-0005-20250824","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first\u2010line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non\u2010inferiority trial","volume":"391","year":"2018","journal-title":"Lancet"},{"issue":"20","key":"hep32468-bib-0006-20250824","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","year":"2020","journal-title":"N Engl J Med"},{"issue":"3_suppl","key":"hep32468-bib-0007-20250824","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1200\/JCO.2021.39.3_suppl.267","article-title":"IMbrave150: Updated overall survival (OS) data from a global, randomized, open\u2010label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)","volume":"39","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"hep32468-bib-0008-20250824","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","year":"2009","journal-title":"Eur J Cancer"},{"issue":"11","key":"hep32468-bib-0009-20250824","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.3390\/cancers13112786","article-title":"Initial experience of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in real\u2010world clinical practice","volume":"13","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"hep32468-bib-0010-20250824","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.annonc.2021.10.008","article-title":"VP10\u20102021: cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first\u2010line systemic treatment for advanced hepatocellular carcinoma (aHCC): results from the randomized phase III COSMIC\u2010312 trial","volume":"33","year":"2022","journal-title":"Ann Oncol"},{"issue":"4_suppl","key":"hep32468-bib-0011-20250824","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1200\/JCO.2022.40.4_suppl.379","article-title":"Phase 3 randomized, open\u2010label, multicenter study of tremelimumab (T) and durvalumab (D) as first\u2010line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA","volume":"40","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"hep32468-bib-0012-20250824","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2021.04.047","article-title":"CheckMate 040 cohort 5: a phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child\u2010Pugh B cirrhosis","volume":"75","year":"2021","journal-title":"J Hepatol"},{"issue":"2","key":"hep32468-bib-0013-20250824","article-title":"Post\u2010registration experience of nivolumab in advanced hepatocellular carcinoma: an international study","volume":"8","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"18","key":"hep32468-bib-0014-20250824","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1002\/cncr.32206","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma and Child\u2010Pugh class B cirrhosis: safety and clinical outcomes in a retrospective case series","volume":"125","year":"2019","journal-title":"Cancer"},{"issue":"2","key":"hep32468-bib-0015-20250824","article-title":"Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy","volume":"8","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"7","key":"hep32468-bib-0016-20250824","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.3390\/cancers12071862","article-title":"Immunotherapy in hepatocellular cancer patients with mild to severe liver dysfunction: adjunctive role of the ALBI grade","volume":"12","year":"2020","journal-title":"Cancers (Basel)"},{"key":"hep32468-bib-0017-20250824","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ejca.2021.08.020","article-title":"Treatment\u2010related toxicity and improved outcome from immunotherapy in hepatocellular cancer: evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice","volume":"157","year":"2021","journal-title":"Eur J Cancer"},{"issue":"2","key":"hep32468-bib-0018-20250824","article-title":"Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: early clinical experience","volume":"5","year":"2022","journal-title":"Cancer Rep (Hoboken)"},{"issue":"3","key":"hep32468-bib-0019-20250824","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/liv.15102","article-title":"Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma","volume":"42","year":"2022","journal-title":"Liver Int"},{"issue":"1","key":"hep32468-bib-0020-20250824","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"hep32468-bib-0021-20250824","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000515302","article-title":"Comparative efficacy of atezolizumab plus bevacizumab and other treatment options for patients with unresectable hepatocellular carcinoma: a network meta\u2010analysis","volume":"10","year":"2021","journal-title":"Liver Cancer"},{"issue":"15_suppl","key":"hep32468-bib-0022-20250824","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.2021.39.15_suppl.4073","article-title":"IMbrave150: exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and\/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study","volume":"39","year":"2021","journal-title":"J Clin Oncol"},{"issue":"8","key":"hep32468-bib-0023-20250824","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1111\/liv.14977","article-title":"Portal hypertension and hepatocellular carcinoma: Des liaisons dangereuses\u2026","volume":"41","year":"2021","journal-title":"Liver Int"},{"issue":"12","key":"hep32468-bib-0024-20250824","article-title":"Efficacy and safety of bevacizumab for the treatment of advanced hepatocellular carcinoma: a systematic review of phase II trials","volume":"7","year":"2012","journal-title":"PLoS One"},{"issue":"10","key":"hep32468-bib-0025-20250824","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1158\/2159-8290.CD-20-0773","article-title":"Clinical portrait of the SARS\u2010CoV\u20102 epidemic in European patients with cancer","volume":"10","year":"2020","journal-title":"Cancer Discov"},{"issue":"7","key":"hep32468-bib-0026-20250824","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S1470-2045(21)00151-0","article-title":"Patient\u2010reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open\u2010label, randomised, phase 3 trial","volume":"22","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"hep32468-bib-0027-20250824","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/lci2.37","article-title":"Treating patients with advanced hepatocellular carcinoma and impaired liver function: broadening the reach of anti\u2010cancer therapy","volume":"2","year":"2021","journal-title":"Liver Cancer Int"},{"issue":"4","key":"hep32468-bib-0028-20250824","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jhep.2020.11.026","article-title":"Systemic treatment of HCC in special populations","volume":"74","year":"2021","journal-title":"J Hepatol"},{"issue":"2","key":"hep32468-bib-0029-20250824","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/annonc\/mds343","article-title":"Sorafenib in patients with Child\u2010Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis","volume":"24","year":"2013","journal-title":"Ann Oncol"},{"issue":"7","key":"hep32468-bib-0030-20250824","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors","volume":"58","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"hep32468-bib-0031-20250824","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S1470-2045(19)30145-7","article-title":"Dose recommendations for anticancer drugs in patients with renal or hepatic impairment","volume":"20","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"hep32468-bib-0032-20250824","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/CCO.0000000000000744","article-title":"The evolving treatment paradigm of advanced hepatocellular carcinoma: putting all the pieces back together","volume":"33","year":"2021","journal-title":"Curr Opin Oncol"},{"issue":"15_suppl","key":"hep32468-bib-0033-20250824","article-title":"Lenvatinib (len) plus pembrolizumab (pembro) for the first\u2010line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP\u2010002 study","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"issue":"1","key":"hep32468-bib-0034-20250824","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1159\/000504624","article-title":"Effects of subsequent systemic anticancer medication following first\u2010line lenvatinib: a post hoc responder analysis from the phase 3 REFLECT study in unresectable hepatocellular carcinoma","volume":"9","year":"2020","journal-title":"Liver Cancer"},{"issue":"4","key":"hep32468-bib-0035-20250824","article-title":"Second\u2010line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial","volume":"5","year":"2020","journal-title":"ESMO Open"},{"issue":"2","key":"hep32468-bib-0036-20250824","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2018.04.010","article-title":"Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase III RESORCE trial","volume":"69","year":"2018","journal-title":"J Hepatol"},{"issue":"6","key":"hep32468-bib-0037-20250824","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jhep.2016.07.020","article-title":"Observational registry of sorafenib use in clinical practice across Child\u2010Pugh subgroups: the GIDEON study","volume":"65","year":"2016","journal-title":"J Hepatol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hep.32468","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hep.32468","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.32468","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T23:05:07Z","timestamp":1756076707000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1002\/hep.32468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,8]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.32468","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,8]]},"assertion":[{"value":"2022-01-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}